Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash. The deal adds to Bristol’s CAR T-cell therapies, with Orbital’s lead experimental candidate OTX-201 that is designed to target autoimmune diseases.
Leave A Comment